Company Analysis - Pfizer
It began with Chiron
Many of PowderMed's products originate in another vaccine company - Chiron. In fact, PowderMed was created via the spin-out of the powder injection DNA vaccine technology from Chiron in 2004. Interestingly, Chiron itself was acquired on April 19th 2006 by the sizeable pharmaceutical company Novartis.
PowderMed was created via the spin-out of the powder injection DNA vaccine technology from Chiron in 2004. Interestingly, Chiron itself was acquired on April 19th 2006 by the sizeable pharmaceutical company NovartisNow operating as the Novartis Vaccines subsidiary of Novartis, the former Chiron was an attractive proposition for Novartis to expand its vaccine platform in addition to complementing its portfolio of specialist biopharmaceuticals. Novartis Vaccines is now the fifth largest vaccine business in the world combined with the title of second largest manufacturer of influenza vaccines.
Comparable to what sparkled in Chiron to Novartis is the early-stage pipeline of potential revenue that PowderMed symbolizes to Pfizer incorporating its proprietary PMED technology and vaccines.
In 2004, Chiron reported net products sales of US$451 and 473 million for its vaccines and biopharmaceuticals, respectively. Combined with an alluring pipeline of compounds to drive through development, Chiron's marketed products were also an attractive feature for the acquisition.
Undeniably, PowderMed's H5N1 vaccine posses the prime potential revenue for Pfizer - as Chiron's H5N1 vaccine did for Novartis - with potential for government stockpiles and immunization programmes.
